Abstracts tagged "IL-6 receptor inhibitor"

Abstract Number: 0834 • ACR Convergence 2021
Comparative Effectiveness of TNF Inhibitor vs IL-6 Receptor Inhibitor as Monotherapy or Combination Therapy with Methotrexate in Patients with Rheumatoid Arthritis: Analysis from CorEvitas’ RA Registry
Anthony Sebba¹, Clifton Bingham², Vivian Bykerk³, Stefano Fiore⁴, Kerri Ford⁵, Jud C Janak⁶, Dimitrios Pappas⁶, Taylor Blachley⁶, Swapna Dave⁶, Joel Kremer⁷, Miao Yu⁶ and Ernest Choy⁸, ¹Division of Rheumatology, University of South Florida, Tampa, FL, ²Johns Hopkins University, Baltimore, MD, ³Division of Rheumatology, Hospital for Special Surgery, New York City, NY, ⁴Sanofi, Bridgewater, NJ, ⁵Sanofi, Cambridge, MA, ⁶CorEvitas, LLC, Waltham, MA, ⁷Department of Medicine, Center for Rheumatology, Albany Medical College, Albany, FL, ⁸CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: RA patients who fail to achieve treatment targets with conventional synthetic DMARDs (csDMARDs) can be treated with biologics. Randomized controlled trials (RCTs) have shown…
Abstract Number: 1690 • ACR Convergence 2021
Safety and Efficacy of Long-term Sarilumab Treatment in Patients with Active Rheumatoid Arthritis: EXTEND and MONARCH Open Label Extension Studies
Gerd Burmester¹, Vibeke Strand², Alan Kivitz³, Chih-Chi Hu⁴, Sheldon Wang⁴, Hubert van Hoogstraten⁵, Ray Tao⁶ and Roy Fleischmann⁷, ¹Charité University Medicine Berlin, Berlin, Germany, ²Stanford University School of Medicine, Portola Valley, CA, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Sanofi Genzyme, Bridgewater, NJ, ⁵Sanofi, Bridgewater, NJ, ⁶Sanofi China R&D, Shanghai, China (People's Republic), ⁷Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: In patients who experience intolerance or fail to respond to methotrexate, IL-6 receptor inhibitors (e.g. sarilumab) are one of the recommended options. The aim…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].